Department of Cardiothoracic Surgery, College of Cornell University, New York, NY, USA.
Cancer Discov. 2013 May;3(5):578-89. doi: 10.1158/2159-8290.CD-12-0476. Epub 2013 Apr 30.
Metastatic tumors have been shown to establish permissive microenvironments for metastases via recruitment of bone marrow-derived cells. Here, we show that metastasis-incompetent tumors are also capable of generating such microenvironments. However, in these situations, the otherwise prometastatic Gr1(+) myeloid cells create a metastasis-refractory microenvironment via the induction of thrombospondin-1 (Tsp-1) by tumor-secreted prosaposin. Bone marrow-specific genetic deletion of Tsp-1 abolished the inhibition of metastasis, which was restored by bone marrow transplant from Tsp-1(+) donors. We also developed a 5-amino acid peptide from prosaposin as a pharmacologic inducer of Tsp-1 in Gr1(+) bone marrow cells, which dramatically suppressed metastasis. These results provide mechanistic insights into why certain tumors are deficient in metastatic potential and implicate recruited Gr1(+) myeloid cells as the main source of Tsp-1. The results underscore the plasticity of Gr1(+) cells, which, depending on the context, promote or inhibit metastasis, and suggest that the peptide could be a potential therapeutic agent against metastatic cancer.
The mechanisms of metastasis suppression are poorly understood. Here, we have identified a novel mechanism whereby metastasis-incompetent tumors generate metastasis-suppressive microenvironments in distant organs by inducing Tsp-1 expression in the bone marrow–derived Gr1+myeloid cells. A 5-amino acid peptide with Tsp-1–inducing activity was identified as a therapeutic agent against metastatic cancer.
转移瘤已被证明通过招募骨髓来源的细胞为转移建立允许的微环境。在这里,我们表明,转移性差的肿瘤也能够产生这样的微环境。然而,在这些情况下,原本具有促转移作用的 Gr1(+)髓样细胞通过肿瘤分泌的前蛋白prosaposin 诱导血栓素-1 (Tsp-1) 来产生转移抵抗性微环境。骨髓特异性 Tsp-1 基因缺失消除了对转移的抑制作用,而来自 Tsp-1(+)供体的骨髓移植则恢复了这种抑制作用。我们还从 prosaposin 中开发了一种 5 个氨基酸肽作为 Gr1(+)骨髓细胞中 Tsp-1 的药理诱导剂,可显著抑制转移。这些结果为某些肿瘤缺乏转移潜能的原因提供了机制上的见解,并暗示募集的 Gr1(+)髓样细胞是 Tsp-1 的主要来源。这些结果强调了 Gr1(+)细胞的可塑性,根据具体情况,它们可以促进或抑制转移,并且表明该肽可能是一种针对转移性癌症的潜在治疗剂。
转移抑制的机制尚不清楚。在这里,我们已经确定了一种新的机制,即通过在骨髓来源的 Gr1+髓样细胞中诱导 Tsp-1 表达,转移性差的肿瘤在远处器官中产生转移抑制微环境。鉴定出一种具有 Tsp-1 诱导活性的 5 个氨基酸肽作为治疗转移性癌症的药物。